Hepatocellular carcinoma (HCC) surveillance in at-risk liver disease
HCC surveillance, liver cancer screening, cirrhosis, AFP, ultrasound, LI-RADS · Gastroenterology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Structured 6-monthly surveillance to detect hepatocellular carcinoma early (curable stage) in at-risk patients: all cirrhosis (any cause) and selected non-cirrhotic chronic HBV. Based on liver ultrasound +/- alpha-fetoprotein (AFP), with multiphase CT/MRI for abnormal findings. Early detection enables curative therapy (resection, ablation, transplant).
Red flags
- New liver mass >=10 mm or rising AFP (possible HCC)
- Rapidly rising AFP even with normal US
- New decompensation (could reflect tumour progression / portal vein invasion)
- Portal vein thrombus on imaging (tumour invasion vs bland)
- Bone pain / weight loss (metastatic disease)
Assessment
Differential diagnosis
- Benign liver lesions: haemangioma, focal nodular hyperplasia, regenerative/dysplastic nodule, simple cyst
- Intrahepatic cholangiocarcinoma
- Liver metastasis
- Hepatic adenoma
- Abscess
- Confluent fibrosis mimicking mass
Investigations
- Liver ultrasound every 6 months +/- serum AFP every 6 months - standard surveillance
- Multiphase contrast CT or MRI liver if US shows a nodule >=10 mm or AFP rising/abnormal (characterise with LI-RADS)
- Define the at-risk population: ALL cirrhosis regardless of cause; chronic HBV without cirrhosis if higher risk (Asian men >40, Asian women >50, Africans from younger age, family history of HCC, high HBV DNA/activity)
- Baseline liver synthetic function (bilirubin, INR, albumin, platelets), Child-Pugh / MELD for treatment candidacy
- Contrast-enhanced ultrasound as problem-solving tool where available
- Biopsy only if imaging indeterminate (diagnosis often made on characteristic imaging in cirrhosis)
Management
- Identify and enrol every at-risk patient (all cirrhosis; selected non-cirrhotic HBV) into 6-monthly surveillance
- Perform liver ultrasound (operator-dependent - note if obesity/steatosis limits views; consider CT/MRI alternation) +/- AFP every 6 months
- Normal (no nodule, stable AFP): continue 6-monthly surveillance
- US nodule <10 mm or small AFP rise: short-interval (3-4 month) repeat imaging
- US nodule >=10 mm or significant AFP rise: multiphase CT/MRI and characterise (LI-RADS); diagnostic if arterial hyperenhancement + washout in a cirrhotic liver
- Confirmed HCC: stage (BCLC) and refer to hepatobiliary MDT for curative (resection/ablation/transplant) vs locoregional (TACE/TARE) vs systemic (atezolizumab-bevacizumab) therapy
- Optimise and treat underlying liver disease (antivirals for HBV/HCV, alcohol abstinence, metabolic control) to reduce incidence
Drugs & doses
No pharmacotherapy for surveillance itself - it is an imaging/biomarker programme
Treat underlying disease to lower HCC risk: HBV antivirals (entecavir/tenofovir), HCV DAAs, alcohol abstinence, metabolic optimisation
On confirmed HCC, systemic first-line (advanced, preserved liver function): atezolizumab + bevacizumab, or durvalumab + tremelimumab - oncology/MDT led [verify local]
Avoid hepatotoxins; vaccinate against hepatitis A/B as appropriate
Disposition
Outpatient surveillance programme (hepatology/primary care recall). Confirmed or suspicious lesions to hepatobiliary MDT. This is screening - not an admission pathway unless decompensation/complication.
Complications & pitfalls
- Late/missed diagnosis if surveillance lapses - incurable stage
- Tumour progression with vascular invasion / metastasis
- Decompensation of underlying cirrhosis
- Surveillance harms: false positives, unnecessary biopsy/imaging
- Ultrasound misses tumours in obese/severe steatosis (consider CT/MRI)
Exam pearls
- AASLD/EASL: offer 6-monthly ultrasound +/- AFP to ALL cirrhotic patients (any aetiology) and to selected non-cirrhotic chronic HBV carriers - 6-monthly, not annual.
- In a cirrhotic liver, a nodule >=10 mm with arterial hyperenhancement AND washout on multiphase CT/MRI is diagnostic of HCC without biopsy (LI-RADS 5).
- Successful HCV cure or HBV suppression REDUCES but does NOT eliminate HCC risk in established cirrhosis - continue surveillance.
- Ultrasound sensitivity falls with obesity and steatosis - consider alternating with CT/MRI in difficult-to-image patients.
- A single AFP is neither sensitive nor specific alone - use it as an adjunct to imaging and watch the trend; refer confirmed/indeterminate cases to the hepatobiliary MDT.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.